Clinical Scorecard: Brachytherapy for Uveal Melanoma: Is the Dose Too High?

At a Glance

Key Highlights

• 85 Gy is the established standard dose for medium-sized tumors but may not be optimal for smaller tumors.
• Lower doses (e.g., 62.5 Gy) can achieve comparable local control with reduced ocular toxicity.
• Personalized plaque design can significantly reduce radiation exposure to critical structures.
• Current evidence suggests a shift towards individualized dosing based on tumor size and location.
• Prospective trials are needed to evaluate the efficacy of reduced-dose regimens.

Guideline-Based Recommendations

Diagnosis

• Use imaging techniques like A-scan ultrasonography for tumor characterization.

Management

• Consider brachytherapy with individualized dosing strategies, especially for smaller tumors.

Monitoring & Follow-up

• Regular follow-up for complications such as radiation retinopathy and optic neuropathy.

Risks

• Higher doses are associated with increased complications, including vision loss.

Patient & Prescribing Data

Patients with uveal melanoma, particularly those with tumors ≤5 mm in height.

Lower doses may provide adequate tumor control while preserving vision.

Clinical Best Practices

• Employ advanced imaging and 3D dosimetry for optimal plaque positioning.
• Adjust radiation doses based on tumor characteristics and patient anatomy.
• Collaborate between ocular oncologists and retina specialists for comprehensive care.

References

• Collaborative Ocular Melanoma Study (COMS)
• Systematic Review of Brachytherapy Dosing
• Ocular Oncology Study Consortium Survey